Research Advances in Ocular Myasthenia Gravis.

Author: Ya Jun WU ¹ ; Li YAN ¹ ; Yu Xiang HU ¹ ; Jie RAO ¹ ; Xiao Xuan XU ¹ ; Yi CHENG ¹ ; Na WU ¹ ; Xiao Rong WU ¹
Author Information

1. Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,China.
Publication Type:Journal Article
MeSH: Antibodies; Complement System Proteins; Cytokines; Humans; Myasthenia Gravis; diagnosis; pathology; therapy; Oculomotor Muscles; pathology
From: Acta Academiae Medicinae Sinicae 2019;41(3):402-407
CountryChina
Language:Chinese
Abstract: Ocular myasthenia gravis(OMG)is an autoimmune disease caused by neuromuscular junction transmission disorders and manifested mainly as fluctuating blepharoptosis and diplopia,with the extraocular muscles as the main involveed sites.While the pathogenesis of OMG remains unclear,some antibodies,complements,and cytokines may be the contributing factors.The diagnosis and treatment of OMG have been defined in recent years.This article reviews the pathogenesis,diagnosis,and treatment of OMG.